BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma
Shots:
- The P-III TiNivo-2 study involves assessing Fotivda (1.34 mg/qd for 21days followed by 7days off treatment) + Opdivo (480 mg- q4w) in ~326 patients in a ratio (1:1) with advanced r/r metastatic RCC following prior immunotherapy exposure
- The study plans to enroll patients across the US- EU- and Latin America. The 1EP of the study is PFS while the 2EPs include OS- ORR- DoR & safety
- Additionally- BMS will provide Opdivo clinical drug supply for the study and AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution
Ref: Businesswire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com